High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment

Abstract Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m2)-conta...

Full description

Bibliographic Details
Main Authors: Yoshitaka Saito, Ryota Kanno, Yoh Takekuma, Takashi Takeshita, Tomohiro Oshino, Mitsuru Sugawara
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-36264-4